.jpeg)
{{ variable.name }}
Lispran tablets are primarily used to treat spinal muscular atrophy (SMN), a rare genetic neuromuscular disease that primarily affects infants and children but may also occur in adults.
1. Common name : Risdiplam (Risdiplam)
2. Trade name u200 c:EVRYSDI™
3. Dosage form :Oral solution (powder needs to be prepared)
4. Main ingredient :Each bottle contains liximalan 60m g, the concentration after preparation is 0.75mg/mL
5. Excipients : Ascorbic acid, disodium edetate, isomalt, mannitol, polyethylene glycol 6000, sodium benzoate, strawberry flavor, trichloride Sucrose, tartaric acid
Spinal Muscular Atrophy (SMA) : Used to treat SMA (including infantile type and late-onset type) in patients 2 months old and above.
1. Specifications : 60mg/bottle (80mL after preparation, concentration 0.75mg/mL)
2. Properties : The powder is light yellow to light green, and after preparation it is a yellow-green to yellow clear liquid.
1. Preparation of : Prepare by a pharmacist with 79mL purified water, shake well and let it sit for 10 minutes.
2. Dose :
2 months to <2 years old: 0.2mg/kg/day
≥2 years old and weight <20kg: 0.25mg/kg/day
≥2 years old and weighing ≥20kg: 5mg/day
3. Administration method : Once a day, take orally or through a feeding tube after a meal, drink water after administration to ensure complete swallowing.
4. Treatment of missed doses of : You can take it within 6 hours, skip it if it exceeds 6 hours; there is no need to take it after vomiting.
1. Hepatic insufficiency : Disabled in moderate to severe (Child-PughB/C).
2. Renal insufficiency : No adjustment required.
1. Monitoring requirements : Regularly check liver function, blood routine and growth and development indicators.
2. Special reminder :
After preparation, the solution needs to be refrigerated in the dark (2-8°C) and discarded after 64 days.
Avoid contact with skin or mucous membranes. If contact occurs, rinse immediately.
Do not mix with formula or milk.
1. Pregnant women :Based on animal data, it may cause harm to the fetus, so the pros and cons need to be weighed.
2. Lactation : Suspend breastfeeding (the drug may be secreted into breast milk).
3. Children : The safety of children under 2 months of age has not been established.
4. Elderly : No dosage adjustment is required.
1. Common (≥10%) :
Infant type: fever, upper respiratory tract infection, pneumonia, constipation, vomiting, diarrhea, rash.
Late onset: fever, diarrhea, rash, oral ulcers.
2. Serious but rare : Retinal toxicity (animal data), QT interval prolongation.
1. Those who are allergic to rispalan or excipients.
2. Moderate to severe liver insufficiency (Child-PughB/C).
1. MATE transporter substrate (such as metformin) : Avoid combined use (may increase toxicity).
2. CYP3A inhibitor/inducer : No significant effect.
1. Unprepared powder : Store at room temperature (15-30°C) in the original packaging and away from light.
2. Prepared solution : Refrigerate (2-8°C) and discard after 64 days.
Manufacturer :Genentech, Inc. (USA, member of Roche Group).
Note : If you have persistent fever, vision changes or severe diarrhea during medication, you need to seek medical treatment in time. Specific medication needs to be prescribed by your doctor.